

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Merck Sharp & Dohme Limited	
Serial No.:	To Be Assigned	Case No.: T1599YP
US Nat'l Filing Date:	April 28, 2005	
Int'l Appl'n No.	PCT/GB03/004728	
Int'l Filing Date:	31 October 2003	
For:	CYCLIC SULFAMIDES FOR INHIBITION OF GAMMA-SECRETASE	

MAIL STOP PCT
Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT April 28, 2005
EXPRESS MAIL NO. EL989580915US

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,
Alexandria, Virginia 22313-1450

MAILED BY Loei Schepisi
DATE 4-28-05

JC17 Rec'd PCT/PTO 28 APR 2005

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

References A-E were listed in the International Search Report during the International phase of this application.


Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of the non-U.S. patent documents that are cited on the attached form PTO-1449 are enclosed herewith.

All the references cited on the attached form were cited in the International Search Report for this application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 
John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: April 28, 2005

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPL. OF KNOWN Application Number JC178B PC178B05/004728 Filing Date April 28, 2005 First Named Inventor Ian James Collins et al. Group Art Unit To Be Assigned Examiner Name To Be Assigned Attorney Docket Number T1599YP		
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	A	US 6,310,107		Kato et al.	10/30/2001
	B	US 5,703,129		Felsenstein et al.	12/30/1997

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	C		WO 02/36555	PCT	Merck Sharp & Dohme Limited	05/10/2002
	D		WO 01/70677	PCT	Merck Sharp & Dohme Limited and	
					Merck Frosst Canada & Co.	09/27/2001

Examiner Signature	Date Considered	
--------------------	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

INFORMATION DISCLOSURE

(use as many sheets as necessary)

2

of

2

T1599YP

COMPLETELY KNOWN

PCT/GB93/00472

April 28, 2005

Ian James Collins et al.

To Be Assigned

To Be Assigned

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

E

G. Rishton et al., "Fenchylamine Sulfonamide Inhibitors of Amyloid Beta Peptide Production by the Gamma-Secretase Proteolytic Pathway: Potential Small-Molecule Therapeutic Agents for the Treatment of Alzheimer's Disease", *J. Med Chem.*, Vol. 43, pp. 2297-2299 (2000)

**Examiner
Signature**

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003